Physician profile
Matthew Milligan
NPI 1508884875
$9,457.06
in general payments reported to CMS, 2019-2025
50 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $1,126 · 2021: $1,554 · 2022: $1,837 · 2023: $1,688 · 2024: $1,153 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,292.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,624.45 | 2021-2025 | |
| Novo Nordisk INC | $1,202.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $977.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $740.01 | 2019-2025 | |
| Amgen INC. | $736.72 | 2019-2025 | Otezla, Repatha, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $574.60 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $515.44 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $408.83 | 2019-2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $256.37 | 2021-2025 | Rexulti |
| Corcept Therapeutics | $195.64 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.91 | 2019-2025 | Xifaxan, Trulance |
| Allergan, INC. | $151.54 | 2019-2020 | |
| Exact Sciences Corporation | $120.10 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $109.97 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $108.44 | 2019-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Milligan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.